Home/ Stocks/ ACOG

Alpha Cognition Inc. Common Stock

ACOG XNAS

$9.13 +0.64 (+7.38%) ▲ 15-min delayed

Open

$8.80

High

$9.21

Low

$8.60

Volume

31.1K

Market Cap

$188.78M

About Alpha Cognition Inc. Common Stock

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 71 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$3.53M	$-6,478,018	$-0.30
FY 2025	$10.22M	$-20,669,875	$-1.17
Q3 2025	$2.84M	$-1,318,074	$-0.08
Q2 2025	$1.66M	$-10,488,952	$-0.65

Related Market News

No specific coverage for ACOG yet. Check out our latest market news or earnings calendar.

Get ACOG Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Alpha Cognition Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.